Skip to content
Optionomics Free · No account needed

Earnings analysis · 10-Q

PRAX earnings analysis

Filed May 7, 2026 · Our reading of the company's report

The latest report

Praxis Precision Medicines, Inc. reported its Q1 2026 results with a substantial net loss of $92.6 million, driven by increased operating expenses, particularly in research and development. The company's ongoing…

Read full summary

Praxis Precision Medicines, Inc. reported its Q1 2026 results with a substantial net loss of $92.6 million, driven by increased operating expenses, particularly in research and development. The company's ongoing evaluation of its product candidates remains critical for future profitability, hinged on successful clinical developments and regulatory approvals.

Read the original on SEC.gov

What stood out

  • Increased Operating Expenses

    Total operating expenses rose to $105.9 million in Q1 2026 from $74.7 million in Q1 2025, an increase of $31.1 million.

  • R&D Spending Up

    Research and development expenses increased by $17.2 million to $78.0 million in Q1 2026 compared to $60.8 million in Q1 2025.

  • Cash Reserves Robust

    Cash, cash equivalents, and marketable securities stand strong at $1.4 billion as of March 31, 2026.

  • Higher General and Admin Costs

    General and administrative expenses surged to $27.9 million in Q1 2026 from $13.9 million in Q1 2025, indicating a rise of $13.9 million.

  • Positive NDA Submissions

    NDA applications for ulixacaltamide and relutrigine have been submitted and accepted for review, with respective PDUFA action dates of January 29, 2027 and September 27, 2026.

  • Financing Activity Strong

    The company raised approximately $609.4 million in Q1 2026 through financing activities, a notable increase from $54.3 million in Q1 2025.

What to watch

  • Significant Quarterly Loss

    The net loss for Q1 2026 was $92.6 million, significantly higher than the $69.3 million loss in Q1 2025.

  • Lack of Revenue Generation

    Praxis has not yet generated any revenue from product sales since inception, relying solely on financing activities.

  • Long Path to Profitability

    With no products on the market, there is uncertainty regarding the timeline and ability to achieve profitability.

Management's outlook

Outlook deferred to earnings press release / call.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.